Featured Research

from universities, journals, and other organizations

Y-90 radioembolization offers promise for late-stage liver cancer

Date:
December 20, 2010
Source:
Indiana University School of Medicine
Summary:
The latest weapon against inoperable liver cancer is so tiny that it takes millions of them per treatment, but according to interventional radiologists, those microscopic spheres really pack a therapeutic punch.

The latest weapon against inoperable liver cancer is so tiny that it takes millions of them per treatment, but according to interventional radiologists at the Indiana University School of Medicine, those microscopic spheres really pack a therapeutic punch.

The glass spheres contain a radioactive element, yttrium-90, more commonly known as Y-90, which emits radiation for a very limited distance so that healthy tissue around the tumor remains unaffected. (2.5mm or less than 1/16th inch in soft tissue).

Y-90 microsphere radioembolization is an FDA-approved procedure first used in the United States in 2002. The outpatient procedure has gained favor with interventional radiologists for treating a type of cancer that is becoming more prevalent due to an increase in the cases of hepatitis and obesity, which along with alcoholism are the three primary causes of liver cancer.

Daniel E. Wertman Jr., M.D., co-director of vascular and interventional radiology and assistant professor of clinical radiology at the Indiana University School of Medicine, said more than 300 patients have been treated with Y-90 radioembolization since the program was initiated at Indiana University Hospital and the Indiana University Melvin and Bren Simon Cancer Center more than 3 years ago.

"I'm really excited about the treatment," said Dr. Wertman. "I think it's probably the best thing that has happened in our specialty."

His colleague, Matthew S. Johnson, M.D., professor of radiology and surgery at IU, reports very positive results with critically ill patients undergoing the treatment. Forty percent of his patients treated with radioembolization had tumors shrink or remain stable at three months. This is exceptional news since patients with advanced liver cancer have few options, he explained.

"I am not aiming for a cure, I'm aiming to extend their lives and make them feel better," said Dr. Johnson.

Physicians agree that liver cancer is a very complex disease. "With the Y-90 radioembolization, the disease can be address with a minimally invasive treatment and through a little band-aid sized incision we can solve very complicated problems," said Dr. Wertman.

A catheter is inserted through a tiny incision in the groin and threaded through the arteries until it reaches the hepatic artery, one of two blood vessels feeding the liver.

The physiology of the liver makes it an ideal organ for this type of treatment. The hepatic artery is the one that most commonly supplies blood to the cancerous tumors.

When the catheter is in the proper place, millions of the microscopic beads containing Y-90 are released. The microspheres lodge in the smaller vessels that directly feed the tumor, stopping blood flow and emitting radiation to kill the tumor cells.

Patients need not be isolated after treatment with Y-90 and usually are released about three hours after the treatment.

What Y-90 offers, Dr. Johnson said, is optimism. "Hope is a magical thing."


Story Source:

The above story is based on materials provided by Indiana University School of Medicine. Note: Materials may be edited for content and length.


Cite This Page:

Indiana University School of Medicine. "Y-90 radioembolization offers promise for late-stage liver cancer." ScienceDaily. ScienceDaily, 20 December 2010. <www.sciencedaily.com/releases/2010/12/101214181951.htm>.
Indiana University School of Medicine. (2010, December 20). Y-90 radioembolization offers promise for late-stage liver cancer. ScienceDaily. Retrieved August 22, 2014 from www.sciencedaily.com/releases/2010/12/101214181951.htm
Indiana University School of Medicine. "Y-90 radioembolization offers promise for late-stage liver cancer." ScienceDaily. www.sciencedaily.com/releases/2010/12/101214181951.htm (accessed August 22, 2014).

Share This




More Health & Medicine News

Friday, August 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Newsy (Aug. 21, 2014) An experimental drug used to treat Marburg virus in rhesus monkeys could give new insight into a similar treatment for Ebola. Video provided by Newsy
Powered by NewsLook.com
Cadavers, a Teen, and a Medical School Dream

Cadavers, a Teen, and a Medical School Dream

AP (Aug. 21, 2014) Contains graphic content. He's only 17. But Johntrell Bowles has wanted to be a doctor from a young age, despite the odds against him. He was recently the youngest participant in a cadaver program at the Indiana University NW medical school. (Aug. 21) Video provided by AP
Powered by NewsLook.com
American Ebola Patients Released: What Cured Them?

American Ebola Patients Released: What Cured Them?

Newsy (Aug. 21, 2014) It's unclear whether the American Ebola patients' recoveries can be attributed to an experimental drug or early detection and good medical care. Video provided by Newsy
Powered by NewsLook.com
Lost Brain Cells To Blame For Sleep Problems Among Seniors

Lost Brain Cells To Blame For Sleep Problems Among Seniors

Newsy (Aug. 21, 2014) According to a new study, elderly people might have trouble sleeping because of the loss of a certain group of neurons in the brain. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins